Title
Role of Olfaction in Human Health: A Focus on Coronaviruses.

Permalink
https://escholarship.org/uc/item/2kh365p1

Authors
Jaime-Lara, Rosario B
Parma, Valentina
Yan, Carol H
et al.

Publication Date
2020

DOI
10.1177/2152656720928245

Peer reviewed
Role of Olfaction in Human Health: A Focus on Coronaviruses

Rosario B. Jaime-Lara, PhD¹, Valentina Parma, PhD², Carol H. Yan, MD³, Farhoud Faraji, MD, PhD³, and Paule V. Joseph, PhD¹

The COVID-19 pandemic has been accompanied by increasing reports of smell and taste impairment in patients infected by its etiologic agent, SARS-CoV-2. An increasing number of studies and more recently a meta-analysis have supported these reports.¹ - ⁴ The Centers for Disease Control and Prevention (CDC) has recently added “new loss of taste or smell” to their list of symptoms of COVID-19.⁵ These sensory changes may hold important implications for the diagnosis and management of COVID-19. Viral upper respiratory infections are among the most common causes of olfactory disorders, and viral etiology accounts for 19% to 43% of patients who present with olfactory dysfunction.⁶ SARS-CoV-2 belongs to the coronavirus family, which is associated with a mild to moderate upper respiratory tract infection widely known as the common cold.⁷ Human coronavirus strains are often accompanied by temporary taste and smell (together henceforth referred to as “chemosensory”) impairments such as diminished sense of smell (hyposmia) and taste (dysgeusia),⁷ often attributed to a virus-induced sinonasal mucosal inflammatory response (rhinitis). More recently, 3 human coronaviruses—the Middle East Respiratory Syndrome,⁸ Severe Acute Respiratory Syndrome (SARS), and SARS-CoV-2—have displayed more severe pathogenicity and symptomatology, potentially including more severe and persistent loss of smell (anosmia) or loss of taste (ageusia). Indeed, an unspecified human coronavirus strain was isolated from a patient with confirmed postviral olfactory dysfunction.⁹

In the case of COVID-19, health-care professionals and scientists around the world have noted a rise in reports of smell and taste impairments. A brief report of 88 patients hospitalized with SARS-CoV-2 infection in Italy found that 34% reported at least 1 olfactory or gustatory complaint.⁵ Ninety percent of these chemosensory impairments occurred prior to hospitalization, and all participants reported that symptoms persisted to the time of the survey was conducted 10 to 21 days later (median of 15 days).² Studies in the United States and across Europe have also highlighted smell and taste dysfunction in COVID-19 patients.¹, ³, ⁴ In the United States, among an ambulatory population of 1,480 patients with influenza-like symptoms (including 102 COVID-19 positive patients), there was a strong correlation between chemosensory dysfunction and COVID-19.⁴ Another study with 417 mild-to-moderate COVID-19 patients across twelve European hospitals found 86% and 89% of COVID-29 patients reported smell and taste dysfunction, respectively.³ A recent meta-analysis of COVID-19 patients reported a 52.73% and 43.93% prevalence of olfactory and gustatory dysfunction, respectively.¹ Unlike coronaviruses responsible for the common cold, patients with COVID-19 have reported olfactory dysfunction in the absence of nasal obstruction or nasal discharge, suggesting SARS-CoV-2-related anosmia has a distinct etiology. A potential mechanism of SARS-CoV-2-related anosmia is viral-induced olfactory neuropathy (Figure 1), which has been shown in a murine model of SARS-CoV.¹⁰ Notably, the novel strain of SARS-CoV-2 infection is not typically associated with rhinitis.

The COVID-19 pandemic serves as a poignant reminder of the relevance of the chemical senses to human health and stresses the need to include smell and taste in clinical assessments. Despite the critical importance of the chemical senses in daily life, they

¹Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland
²Department of Psychology, Temple University, Philadelphia, Pennsylvania
³Department of Surgery, Division of Otolaryngology—Head and Neck Surgery, UC San Diego, La Jolla, California

Corresponding Author:
Paule V. Joseph, Department of Health and Human Services, National Institute of Nursing Research, National Institutes of Health, Rm 258, Bldg 60, 1 Cloister Court, Bethesda, MD 20892, USA.
Email: paule.joseph@nih.gov
remain understudied in the context of health and disease. Although in rare cases the preservation of smell is used in differential diagnoses (e.g., Parkinson’s disease vs vascular Parkinsonism), health professionals rarely incorporate examination of the chemical senses in the diagnostic process. Moreover, as evidenced by the limited literature on olfactory and taste science compared to that of visual and auditory science, the chemical senses remain among the more poorly understood special senses. In the absence of a more robust understanding of smell and taste, clinicians are limited in their assessment of chemical sensory dysfunction and may not recognize its significance or association to disease. However, smell and taste sensation are intimately intertwined with mammalian survival. They impact nutritional intake, mood, and serve as important mechanisms for detecting danger; they enable detection of contaminated foods and the presence of harmful and potentially life-threatening chemicals.

Although smell and taste have yet to be systematically evaluated in patients with COVID-19, emerging evidence suggests that chemosensory dysfunction is part of the COVID-19 and is now recognized by the CDC and health departments across the globe.\(^5\)\(^6\)\(^7\)\(^8\)\(^9\)\(^10\)\(^11\) Given the complex interdependent relationship between smell and taste, anosmia may be reported as gustatory changes. With regard to taste, true ageusia (independent of smell) is rare, and discerning its prevalence in COVID-19 patients may be difficult. Nonetheless, data examining the prevalence of chemosensory dysfunction is only beginning to emerge and its prevalence in patients with COVID-19 remains largely understudied.

In the context of the COVID-19 pandemic, appreciating the potential effects on smell and taste may aid in early diagnosis and containment efforts. Importantly, currently available reports and emerging studies indicate that olfactory dysfunction presents early in infection.\(^1\)\(^2\)\(^3\) If confirmed and highly prevalent, chemosensory changes could be included in the early COVID-19 symptom profile used to recommend isolation and prevent the spread of the virus. The establishment of hyposmia, anosmia, ageusia, and dysgeusia as COVID-19 symptoms can now improve diagnosis and disease containment. Early detection of chemosensory impairment may also serve to reduce the burden of potential complications related to anosmia and ageusia in patients with COVID-19; however, research is needed to establish this.

Many questions remain regarding the role of SARS-CoV-2 in chemosensory dysfunction. Does SARS-CoV-2 cause or is it merely correlated with chemosensory dysfunction? If it is indeed an etiologic agent, what is the penetrance of SARS-CoV-2-related chemosensory dysfunction? What clinicopathological factors are associated with SARS-CoV-2-related chemosensory dysfunction? Is SARS-CoV-2-related chemosensory dysfunction complete (anosmia or ageusia) or partial (hyposmia or hypogeusia)? How long does SARS-CoV-2-related chemosensory dysfunction persist or how much does the length of symptoms vary across populations? Can methods used to support olfactory function, such as smell training,\(^12\)\(^13\) help in the recovery of COVID-19 chemosensory symptoms?

Further research is necessary to establish the prevalence, duration, and pathophysiology of SARS-CoV-2-related chemosensory dysfunction, and to identify which olfactory and/or gustatory patterns may be most helpful in the diagnosis and prognosis of COVID-19. To fully interrogate the occurrence of chemosensory issues in this patient population, large-scale, natural history studies using validated psychophysical instruments to map over time olfactory (as in Moein et al.\(^14\)) and gustatory changes (e.g., taste strips,\(^15\) NIH Toolbox Sensation Measures and others\(^16\)\(^17\)) are necessary.

**Acknowledgment**

Mr. Alan Hoofring, MS, MA Lead, Medical Illustration for the National Institutes of Health Medical Arts Design Section.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical Approval**

Not applicable.
**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: R. B. J. L. is supported by an Intramural Research Training Award, Office of Intramural Training & Education, National Institutes of Health, Department of Health and Human Services. P. V. J. is supported by the National Institute of Nursing Research under award number 1ZIANR000035-01. P. V. J. is also supported by the Office of Workforce Diversity, National Institutes of Health and the Rockefeller University Heilbrunn Nurse Scholar Award.

**ORCID iD**

Paule V. Joseph [https://orcid.org/0000-0002-1198-9622](https://orcid.org/0000-0002-1198-9622)

**Statement of Human and Animal Rights**

This article does not contain any studies with human or animal subjects.

**Statement of Informed Consent**

There are no human subjects in this article and informed consent is not applicable.

**References**

1. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. *Otolaryngol Head Neck Surg*. 2020. doi: 10.1177/0194599820926473
2. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis*. 2020. doi: 10.1093/cid/ciaa330
3. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020. doi: 10.1007/s00405-020-05965-1
4. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. *Int Forum Allergy Rhinol*. 2020. doi: 10.1002/alr.22579
5. Centers for Disease Control and Prevention. Symptoms of Coronavirus. [https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html#](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html#). Published 2020. Accessed May 7, 2020.
6. Seiden AM. Postviral olfactory loss. *Otolaryngol Clin N Am*. 2004;37:1159–1166.
7. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronavirus—drug discovery and therapeutic options. *Nat Rev Drug Discov*. 2016;15:327–347.
8. Soria-Gómez E, Belloccchio L, Reguero L, et al. The endocannabinoid system controls food intake via olfactory processes. *Nat Neurosci*. 2014;17:407–415.
9. Suzuki M, Saito K, Min W-P, et al. Identification of viruses in patients with postviral olfactory dysfunction. *Laryngoscope*. 2007;117:272–277.
10. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. *ACS Chem Neurosci*. 2020;11:995–998. doi: 10.1021/acschemneuro.0c00122
11. Ministerio de Salud Chile. Consejo Asesor del Ministerio de Salud amplía definición de casos sospechosos y confirmados de COVID-19. [https://www.minsal.cl/consejo-asesor-del-ministerio-de-salud-amplia-definicion-de-casos-sospechosos-y-confirmados-de-covid-19/](https://www.minsal.cl/consejo-asesor-del-ministerio-de-salud-amplia-definicion-de-casos-sospechosos-y-confirmados-de-covid-19/)
12. Hummel T, Rissom K, Reden J, Hahner A, Weidenbecher M, Huttenbrink KB. Effects of olfactory training in patients with olfactory loss. *Laryngoscope*. 2009;119:496–499.
13. Kollndorfer K, Fischmeister FP, Kowalczyk K, et al. Olfactory training induces changes in regional functional connectivity in patients with long-term smell loss. *Neuroimage Clin*. 2015;9:401–410.
14. Moein ST, Hashemian SMR, Mansourafshar B, Khorrampetousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020. doi: 10.1111/alr.22587
15. Landis BN, Welge-Luessen A, Brainer A, et al. “Taste Strips”—a rapid, lateralized, gustatory bedside identification test based on impregnated filter papers. *J Neurol*. 2009;256:242.
16. Coldwell SE, Mennella JA, Duffy VB, et al. Gustation assessment using the NIH Toolbox. *Neurology*. 2013;80:S20.
17. Dalton P, Doty RL, Murphy C, et al. Olfactory assessment using the NIH Toolbox. *Neurology*. 2013;80:S32.